Crispr Therapeutics price target lowered to $67 from $80 at Barclays

Barclays lowered the firm’s price target on Crispr Therapeutics to $67 from $80 and keeps an Equal Weight rating on the shares. The company’s Q1 update was largely incremental, with the focus maintained on Casgevy launch, where five patients initiated cell collection globally, with multiple cell collections completed, the analyst tells investors in a research note.